Aster Capital Management’s Moderna MRNA Stock Holding History

Aster Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,987	Closed	-$498K	–	1530
2024 Q4	$498K	Buy	+11,987	New	+$573K	0.19%	146

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aster Capital Management's MRNA Position: Q1 2025 in Review

Aster Capital Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 11,987 shares — an estimated $498K sold.

Aster Capital Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $498K in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

Aster Capital Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
Aster Capital Management sold 11,987 Moderna shares in Q1 2025, an estimated $498K.
Aster Capital Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
Aster Capital Management's Moderna position peaked at $498K in Q4 2024.
693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Aster Capital Management's 13F filing for Q1 2025, filed 15 May 2025.